Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease - Takeaways - MDSpire

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease

  • By

  • Jie Su

  • Dalia A Lartey

  • Gaia Zanella

  • Lukas J A C Hawinkels

  • Gianluca Matteoli

  • Mark Löwenberg

  • Marieke C Barnhoorn

  • May 24, 2025

  • 0 min

Share

  • 1

    Intestinal fibrosis is a significant complication in IBD, affecting about 50% of Crohn's disease patients and 5% of ulcerative colitis patients.

  • 2

    Currently, no anti-fibrotic drugs exist for IBD, making endoscopic or surgical interventions the only treatment options for intestinal strictures.

  • 3

    The JAK-STAT pathway is crucial in regulating inflammation and fibrosis, activated by various inflammatory cytokines during intestinal inflammation.

  • 4

    JAK inhibitors, approved for IBD, provide rapid oral administration and target multiple inflammatory pathways, showing potential in treating fibrosis.

  • 5

    Research suggests that JAK inhibitors may not only reduce inflammation in IBD but also prevent or treat intestinal fibrosis.

Original Source(s)

Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease

  • by Jie Su, Dalia A Lartey, Gaia Zanella, Lukas J A C Hawinkels, Gianluca Matteoli, Mark Löwenberg, Marieke C Barnhoorn

  • May 24, 2025

Related Content

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

Editorial: Volume II of the Community Series on Gut Microbiota and Immune Interactions in Intestinal Disorders

The innovation trap: How pharma weaponizes a word to extend monopolies